Program
trifluridine tipiracil drug combination
Also written as “TAS-102”, “Trifluridine/Tipiracil” and “Trifluridine and Tipiracil Tablets”.
Its studies are mostly in Colorectal Neoplasms · Breast Neoplasms · Liver Neoplasms · Kidney Diseases · Small Cell Lung Carcinoma, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 130 open or running | phase 3since May 24, 2012 | May 24, 2012 | none ahead |
| Sino Biopharmaceutical | 32 open or running | phase 3since Mar 6, 2026 | May 31, 2019 | Aug 2027phase 3 · NCT07483684 |
| AbbVie | 11 open or running | phase 3since Apr 7, 2026 | Apr 7, 2026 | May 2029phase 3 · NCT07525206 |
| Criterium | 11 open or running | phase 2since Apr 30, 2025 | Apr 30, 2025 | Dec 31, 2027phase 2 · NCT06992258 |
| Elevar Therapeutics | 10 open or running | phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| GamaMabs Pharma | 10 open or running | phase 2since Jan 8, 2019 | Jan 8, 2019 | none ahead |
| Gilead Sciences | 11 open or running | phase 2since Apr 7, 2026 | Apr 7, 2026 | Dec 2028phase 2 · NCT07527858 |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since Dec 26, 2023 | Dec 26, 2023 | none ahead |
| Lunan Pharmaceutical Group | 10 open or running | no phasesince Mar 19, 2026 | Mar 19, 2026 | none ahead |
| STCube | 11 open or running | phase 1since May 27, 2026 | May 27, 2026 | Jul 31, 2028phase 1 · NCT07656038 |
| Takeda | 10 open or running | phase 2since Nov 20, 2015 | Nov 20, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since May 24, 2012.
- Jul 13, 2015Phase 3 study in Stomach NeoplasmsOtsuka · NCT02500043 · 507 enrolled · United States, Belarus, Belgium and more
- Nov 20, 2015Takeda’s first study: phase 2 study in Colorectal NeoplasmsNew to TakedaTakeda · NCT02613221 · 56 enrolled · Japan
- Jul 13, 2016Phase 2 study in Colorectal NeoplasmsOtsuka · NCT02860546 · 18 enrolled · United States
- Jan 8, 2019GamaMabs Pharma’s first study: phase 2 study in Colorectal NeoplasmsNew to GamaMabs PharmaGamaMabs Pharma · NCT03799731 · 65 enrolled · Belgium, Czechia
- May 31, 2019Sino Biopharmaceutical’s first study: phase 1 study in Colorectal NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03974594 · 64 enrolled · China
- Aug 26, 2019Elevar Therapeutics’ first study: phase 1 study in Colorectal NeoplasmsNew to Elevar TherapeuticsElevar Therapeutics · NCT04073615 · 29 enrolled · United States
- Dec 26, 2023Jiangsu HengRui Medicine’s first study: phase 3 study in Advanced Colorectal CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06199973 · 130 enrolled · China
- Apr 30, 2025Criterium’s first study: phase 2 study in Colorectal NeoplasmsNew to CriteriumCriterium · NCT06992258 · 120 planned · United States
- Jun 23, 2025Phase 2 study in RAS/BRAF Wild Type Colorectal CancerSino Biopharmaceutical · NCT07044908 · 72 planned · China
- Mar 6, 2026Phase 3 study in HER2 IHC3+ Advanced Colorectal CancerPhase 3 reachedSino Biopharmaceutical · NCT07483684 · 142 planned · China
- Mar 19, 2026Lunan Pharmaceutical Group’s first study: no phase study in Solid Tumor CancerNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07492173 · 76 enrolled · China
- Apr 7, 2026Gilead Sciences’ first study: phase 2 study in Advanced Microsatellite Stable Colorectal CancerNew to Gilead SciencesGilead Sciences · NCT07527858 · 170 planned · United States, Australia, South Korea and more
- Apr 7, 2026AbbVie’s first study: phase 3 study in Colorectal NeoplasmsNew to AbbVieAbbVie · NCT07525206 · 990 planned · United States, Belgium, China and more
- May 27, 2026STCube’s first study: phase 1 study in Colonrectal Cancer (CRC)New to STCubeSTCube · NCT07656038 · 45 planned
Ahead
- Aug 2027Primary completion: phase 3 study in HER2 IHC3+ Advanced Colorectal CancerSino Biopharmaceutical · NCT07483684
- Dec 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCriterium · NCT06992258
- Jul 31, 2028Primary completion: phase 1 study in Colonrectal Cancer (CRC)STCube · NCT07656038
- Dec 2028Primary completion: phase 2 study in Advanced Microsatellite Stable Colorectal CancerGilead Sciences · NCT07527858
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07656038Colonrectal Cancer (CRC) | 1 | Not yet recruiting | STCube | Jul 31, 2028 | 45 |
| NCT07527858Advanced Microsatellite Stable Colorectal Cancer · United States, Australia, South Korea and more | 2 | Recruiting | Gilead Sciences | Dec 2028 | 170 |
| NCT07525206Colorectal Neoplasms · United States, Belgium, China and more | 3 | Recruiting | AbbVie | May 2029 | 990 |
| NCT07492173Solid Tumor Cancer · China | – | Completed | Lunan Pharmaceutical Group | Jun 25, 2023 | 76 |
| NCT07483684HER2 IHC3+ Advanced Colorectal Cancer · China | 3 | Not yet recruiting | Sino Biopharmaceutical | Aug 2027 | 142 |
| NCT07044908RAS/BRAF Wild Type Colorectal Cancer · China | 2 | Recruiting | Sino Biopharmaceutical | Jul 2026 | 72 |
| NCT06992258Colorectal Neoplasms · United States | 2 | Recruiting | Criterium | Dec 31, 2027 | 120 |
| NCT06199973Advanced Colorectal Cancer · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Apr 2026 | 130 |
| NCT04073615Colorectal Neoplasms · United States | 1 | Terminated | Elevar Therapeutics | May 31, 2023 | 29 |
| NCT03974594Colorectal Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Jul 16, 2019 | 64 |
| NCT03799731Colorectal Neoplasms · Belgium, Czechia | 2 | Completed | GamaMabs Pharma | Jan 19, 2021 | 65 |
| NCT02860546Colorectal Neoplasms · United States | 2 | Completed | Otsuka | Aug 2017 | 18 |
| NCT02613221Colorectal Neoplasms · Japan | 2 | Completed | Takeda | Oct 6, 2017 | 56 |
| NCT02500043Stomach Neoplasms · United States, Belarus, Belgium and more | 3 | Completed | Otsuka | Apr 30, 2018 | 507 |
| NCT02301117Kidney Diseases · United States, Czechia, Serbia | 1 | Completed | Otsuka | Jun 19, 2019 | 43 |
| NCT02301104Liver Neoplasms · United States | 1 | Completed | Otsuka | Jun 2016 | 24 |
| NCT02261532Advanced or Metastatic Solid Tumors · China | 1 | Completed | Otsuka | Oct 2015 | 15 |
| NCT02031055Advanced Solid Tumors · United States | 1 | Completed | Otsuka | Nov 2014 | 8 |
| NCT01955837Colorectal Neoplasms · China, Korea, Republic of, Thailand | 3 | Completed | Otsuka | Feb 16, 2016 | 406 |
| NCT01916447Advanced Gastrointestinal Tumors · United States | 1 | Completed | Otsuka | Sep 2017 | 65 |
| NCT01904253Small Cell Lung Carcinoma · Germany, Italy, Japan | 2 | Terminated | Otsuka | Jun 2014 | 18 |
| NCT01874522Advanced Solid Tumors (Excluding Breast Cancer) · United States | 1 | Completed | Otsuka | Aug 2015 | 46 |
| NCT01867879Advanced Solid Tumors (Excluding Breast Cancer) · United States | 1 | Completed | Otsuka | Aug 2014 | 44 |
| NCT01867866Advanced Solid Tumors · United States | 1 | Completed | Otsuka | Oct 2013 | 44 |
| NCT01607957Colorectal Neoplasms · United States, Australia, Austria and more | 3 | Completed | Otsuka | Jan 31, 2014 | 800 |
How it is read
Names in the registry
- “TAS-102”, 11 entries
- “Trifluridine/Tipiracil”, 3 entries
- “Trifluridine and Tipiracil Tablets”, 2 entries
- “Trifluridine-Tipiracil”, 1 entry
- “Fruquintinib+ Lonsurf (trifluridine and tipiracil)”, 1 entry
Codes read as this program: TAS102.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 13 studies
- Breast Neoplasms, 2 studies
- Liver Neoplasms, 1 study
- Kidney Diseases, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.